Maker of Motiva breast implants using proprietary silicone technology, sold internationally outside the US mostly.
Maker of Motiva breast implants using proprietary silicone technology, sold internationally outside the US mostly.
Manufactures in Costa Rica and sells implants to surgeons, directly in some countries and through distributors elsewhere, mostly as cosmetic procedures patients pay for themselves rather than insurers. Sales have been largely outside the US, so the US launch after FDA approval in 2024 is the biggest change.
Moat: narrow (IP / patents, brand, regulatory licence). Proprietary implant technology and design differentiate from legacy Allergan/Mentor implants amid industry safety concerns.
Headquarters: Alajuela, Costa Rica · Founded: 2004 · Employees: 1,004
Size Establishment Labs (ESTA) is a United States Health Care company (Medical Specialties) with a market value of $2.11B, the 1741st largest of 3,085 United States companies the cockpit tracks. Shares closed at $70.80 on 18 Nov 2026.
Performance Over six months the shares gained 1.1%, against +3.1% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 38.2% over the last twelve months (peer median +7.5%); the operating margin is -6.6% (peer median 15.2%).
Valuation It trades at 8.7× enterprise value to sales against a peer median of 4.0× (4th most expensive of 21).
Capital Return on invested capital runs 16.2 points below its cost of capital (9.7% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $264M | $211M | $166M | $165M | $162M |
| Revenue growth | — | +27% | +1% | +2% | — |
| Gross profit | $185M | $146M | $110M | $107M | $107M |
| EBITDA | -$6.12M | -$28.5M | -$42.4M | -$60.1M | -$35.5M |
| Net income | -$38.5M | -$51.1M | -$84.6M | -$78.5M | -$75.2M |
| Free cash flow | -$22.6M | -$56.9M | -$67.0M | -$112M | -$84.9M |
| Capital expenditure | $10.2M | $6.72M | $15.6M | $24.5M | $34.8M |
| Total debt | $270M | $264M | $225M | $192M | $179M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Establishment Labs ESTA | $2.11B | +1% | +38% | -7% | 8.7× | n/a |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ESTA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.9% | -0.8% | 5th highest of 21 |
| 6-month return | +1.1% | +3.1% | 10th lowest of 20 |
| Distance from 52-week high | -27.4% | -18.1% | 7th lowest of 21 |
| Revenue growth (TTM) | +38.2% | +7.5% | highest of 21 |
| Operating margin | -6.6% | 15.2% | 2nd lowest of 21 |
| EV / Sales | 8.7× | 4.0× | 4th most expensive of 21 |
| ROIC minus cost of capital | -16.2 pp | +0.6 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | 8.7× | n/a | n/a |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 1.9× | 22.2% | +10.2% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 0.5× | -10.2% | +0.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 3.0× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 14.6× | 12.6% | +45.4% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 10.6× | n/a | n/a |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 6.2× | -1.1% | +14.1% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 4.3× | 11.9% | +19.2% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 1.7× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 6.8× | 6.1% | +0.6% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 5.7× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 4.4× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | 13.1× | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 3.5× | 18.3% | +14.5% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 3.4× | n/a | n/a |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 1.6× | -1.6% | -1.0% |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 5.4× | 7.6% | +10.4% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 0.8× | -12.6% | +2.1% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 3.6× | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 7.7× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 0.4× | 4.7% | +6.8% |